Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | CCR2 | P41597 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12490756 | 0.85 | P2RX7 (0.33) | CCR2KCNH2P2RX7CHRM1TDP1 | |
| SCHEMBL2225191 | 0.85 | P2RX7 (0.33) | CCR2KCNH2P2RX7CHRM1TDP1 | |
| SCHEMBL27617063 | 0.81 | AGTR2 (0.36) | CCR2KCNH2ATMP2RX7CHRM1 | |
| SCHEMBL7254331 | 0.80 | AGTR2 (0.33) | ALDH1A1MAPK1LMNAMAPT | |
| SCHEMBL1536762 | 0.79 | TSHR (0.38) | KMT2AALDH1A1 | |
| SCHEMBL2224868 | 0.78 | ALDH1A1 (0.43) | KMT2AKDM4EALDH1A1MAPK1LMNA | |
| SCHEMBL24310950 | 0.74 | MMP1 (0.35) | CCR2KCNH2ALDH1A1ATMP2RX7 | |
| SCHEMBL23458144 | 0.72 | HSD17B10 (0.43) | ALDH1A1MAPK1LMNAMAPTNPSR1 | |
| SCHEMBL3309798 | 0.71 | ALDH1A1 (0.42) | KMT2AKDM4EALDH1A1LMNAMAPT | |
| SCHEMBL2379763 | 0.71 | CHRM1 (0.49) | KDM4EALDH1A1P2RX7LMNACHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8981084-B2 | Oxadiazole HDAC inhibitors | TEMPERO PHARMACEUTICALS, INC. (US) | 2015-03-17 | — | — | US | disclosed |
| EP-2523664-A1 | COMPOUNDS AND METHODS | Tempero Pharmaceuticals, Inc. (US) | 2012-11-21 | — | — | EP | disclosed |
| US-20120289495-A1 | COMPOUNDS AND METHODS | Tempero Pharmaceuticals Inc. | 2012-11-15 | — | — | US | disclosed |
| WO-2011088192-A1 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. (US) | 2011-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120289495-A1 | COMPOUNDS AND METHODS | XDH, CCNY, TOP2B | KMT2A 2762/4885CCR2 708/4885KCNH2 1203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.